Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment
Abstract
:1. Introduction
2. Role of Metabolic Pathway in Microvascular Complications
3. New Molecular Pathogenesis
3.1. Epigenetics Mechanisms
3.2. Role of Gut Microbiota
3.3. Diabetic Retinopathy
3.4. Treatment and Current Advances in Diabetic Retinopathy
Diabetic Neuropathy
3.5. Treatment and Current Advances in Diabetic Neuropathy
Diabetic Nephropathy
3.6. Treatment and Current Advances in Diabetic Nephropathy
4. Impact of Glucose-Lowering Drugs on Microvascular Complications
Author Contributions
Funding
Conflicts of Interest
References
- Galicia-Garcia, U.; Benito-Vicente, A.; Jebari, S.; Larrea-Sebal, A.; Siddiqi, H.; Uribe, K.B.; Ostolaza, H.; Martin, C. Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci. 2020, 21, 6275. [Google Scholar] [CrossRef] [PubMed]
- Chan, J.C.N.; Lim, L.L.; Wareham, N.J.; Shaw, J.E.; Orchard, T.J.; Zhang, P.; Lau, E.S.H.; Eliasson, B.; Kong, A.P.S.; Ezzati, M.; et al. The Lancet Commission on diabetes: Using data to transform diabetes care and patient lives. Lancet 2021, 396, 2019–2082. [Google Scholar] [CrossRef] [PubMed]
- Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27, 1047–1053. [Google Scholar] [CrossRef] [PubMed]
- Martinez-Ortega, A.J.; Munoz-Gomez, C.; Gros-Herguido, N.; Remon-Ruiz, P.J.; Acosta-Delgado, D.; Losada-Vinau, F.; Pumar-Lopez, A.; Mangas-Cruz, M.A.; Gonzalez-Navarro, I.; Lopez-Gallardo, G.; et al. Description of a Cohort of Type 1 Diabetes Patients: Analysis of Comorbidities, Prevalence of Complications and Risk of Hypoglycemia. J. Clin. Med. 2022, 11, 1039. [Google Scholar] [CrossRef] [PubMed]
- Riddle, M.C.; Cefalu, W.T.; Evans, P.H.; Gerstein, H.C.; Nauck, M.A.; Oh, W.K.; Rothberg, A.E.; le Roux, C.W.; Rubino, F.; Schauer, P.; et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care 2021, 44, 2438–2444. [Google Scholar] [CrossRef]
- Ahmad, E.; Lim, S.; Lamptey, R.; Webb, D.R.; Davies, M.J. Type 2 diabetes. Lancet 2022, 400, 1803–1820. [Google Scholar] [CrossRef]
- Dabelea, D. The accelerating epidemic of childhood diabetes. Lancet 2009, 373, 1999–2000. [Google Scholar] [CrossRef]
- Li, L.; Holscher, C. Common pathological processes in Alzheimer disease and type 2 diabetes: A review. Brain Res. Rev. 2007, 56, 384–402. [Google Scholar] [CrossRef]
- Nguyen, T.T.; Ta, Q.T.H.; Nguyen, T.K.O.; Nguyen, T.T.D.; Giau, V.V. Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease. Int. J. Mol. Sci. 2020, 21, 3165. [Google Scholar] [CrossRef]
- ElSayed, N.A.; Aleppo, G.; Aroda, V.R.; Bannuru, R.R.; Brown, F.M.; Bruemmer, D.; Collins, B.S.; Das, S.R.; Hilliard, M.E.; Isaacs, D.; et al. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes Care 2023, 46, S158–S190. [Google Scholar] [CrossRef]
- Soyoye, D.O.; Abiodun, O.O.; Ikem, R.T.; Kolawole, B.A.; Akintomide, A.O. Diabetes and peripheral artery disease: A review. World J. Diabetes 2021, 12, 827–838. [Google Scholar] [CrossRef] [PubMed]
- Vithian, K.; Hurel, S. Microvascular complications: Pathophysiology and management. Clin. Med. 2010, 10, 505–509. [Google Scholar] [CrossRef]
- Zakir, M.; Ahuja, N.; Surksha, M.A.; Sachdev, R.; Kalariya, Y.; Nasir, M.; Kashif, M.; Shahzeen, F.; Tayyab, A.; Khan, M.S.M.; et al. Cardiovascular Complications of Diabetes: From Microvascular to Macrovascular Pathways. Cureus 2023, 15, e45835. [Google Scholar] [CrossRef]
- Sherwani, S.I.; Khan, H.A.; Ekhzaimy, A.; Masood, A.; Sakharkar, M.K. Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients. Biomark. Insights 2016, 11, 95–104. [Google Scholar] [CrossRef]
- Marcovecchio, M.L.; Lucantoni, M.; Chiarelli, F. Role of chronic and acute hyperglycemia in the development of diabetes complications. Diabetes Technol. Ther. 2011, 13, 389–394. [Google Scholar] [CrossRef]
- Brownlee, M. The pathobiology of diabetic complications: A unifying mechanism. Diabetes 2005, 54, 1615–1625. [Google Scholar] [CrossRef] [PubMed]
- Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001, 414, 813–820. [Google Scholar] [CrossRef]
- Kowalczyk, P.; Sulejczak, D.; Kleczkowska, P.; Bukowska-Osko, I.; Kucia, M.; Popiel, M.; Wietrak, E.; Kramkowski, K.; Wrzosek, K.; Kaczynska, K. Mitochondrial Oxidative Stress-A Causative Factor and Therapeutic Target in Many Diseases. Int. J. Mol. Sci. 2021, 22, 13384. [Google Scholar] [CrossRef] [PubMed]
- Tang, W.H.; Martin, K.A.; Hwa, J. Aldose reductase, oxidative stress, and diabetic mellitus. Front. Pharmacol. 2012, 3, 87. [Google Scholar] [CrossRef]
- Singh, M.; Kapoor, A.; Bhatnagar, A. Physiological and Pathological Roles of Aldose Reductase. Metabolites 2021, 11, 655. [Google Scholar] [CrossRef]
- Lorenzi, M. The polyol pathway as a mechanism for diabetic retinopathy: Attractive, elusive, and resilient. Exp. Diabetes Res. 2007, 2007, 61038. [Google Scholar] [CrossRef] [PubMed]
- Khalid, M.; Petroianu, G.; Adem, A. Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives. Biomolecules 2022, 12, 542. [Google Scholar] [CrossRef] [PubMed]
- Yamagishi, S.; Nakamura, K.; Imaizumi, T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr. Diabetes Rev. 2005, 1, 93–106. [Google Scholar] [CrossRef]
- Nguyen, D.V.; Shaw, L.C.; Grant, M.B. Inflammation in the pathogenesis of microvascular complications in diabetes. Front. Endocrinol. 2012, 3, 170. [Google Scholar] [CrossRef]
- Penn, J.S.; Madan, A.; Caldwell, R.B.; Bartoli, M.; Caldwell, R.W.; Hartnett, M.E. Vascular endothelial growth factor in eye disease. Prog. Retin. Eye Res. 2008, 27, 331–371. [Google Scholar] [CrossRef] [PubMed]
- Kumar Pasupulati, A.; Chitra, P.S.; Reddy, G.B. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy. Biomol. Concepts 2016, 7, 293–309. [Google Scholar] [CrossRef]
- Geraldes, P.; King, G.L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 2010, 106, 1319–1331. [Google Scholar] [CrossRef]
- Pan, D.; Xu, L.; Guo, M. The role of protein kinase C in diabetic microvascular complications. Front. Endocrinol. 2022, 13, 973058. [Google Scholar] [CrossRef]
- Hart, G.W.; Slawson, C.; Ramirez-Correa, G.; Lagerlof, O. Cross talk between O-GlcNAcylation and phosphorylation: Roles in signaling, transcription, and chronic disease. Annu. Rev. Biochem. 2011, 80, 825–858. [Google Scholar] [CrossRef]
- Zochodne, D.W. Diabetic polyneuropathy: An update. Curr. Opin. Neurol. 2008, 21, 527–533. [Google Scholar] [CrossRef]
- Reddy, M.A.; Tak Park, J.; Natarajan, R. Epigenetic modifications in the pathogenesis of diabetic nephropathy. Semin. Nephrol. 2013, 33, 341–353. [Google Scholar] [CrossRef] [PubMed]
- Brasacchio, D.; Okabe, J.; Tikellis, C.; Balcerczyk, A.; George, P.; Baker, E.K.; Calkin, A.C.; Brownlee, M.; Cooper, M.E.; El-Osta, A. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 2009, 58, 1229–1236. [Google Scholar] [CrossRef] [PubMed]
- Feng, B.; Cao, Y.; Chen, S.; Chu, X.; Chu, Y.; Chakrabarti, S. miR-200b Mediates Endothelial-to-Mesenchymal Transition in Diabetic Cardiomyopathy. Diabetes 2016, 65, 768–779. [Google Scholar] [CrossRef]
- Putta, S.; Lanting, L.; Sun, G.; Lawson, G.; Kato, M.; Natarajan, R. Inhibiting microRNA-192 ameliorates renal fibrosis in diabetic nephropathy. J. Am. Soc. Nephrol. 2012, 23, 458–469. [Google Scholar] [CrossRef]
- Yan, B.; Tao, Z.F.; Li, X.M.; Zhang, H.; Yao, J.; Jiang, Q. Aberrant expression of long noncoding RNAs in early diabetic retinopathy. Investig. Ophthalmol. Vis. Sci. 2014, 55, 941–951. [Google Scholar] [CrossRef]
- Zampetaki, A.; Kiechl, S.; Drozdov, I.; Willeit, P.; Mayr, U.; Prokopi, M.; Mayr, A.; Weger, S.; Oberhollenzer, F.; Bonora, E.; et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ. Res. 2010, 107, 810–817. [Google Scholar] [CrossRef]
- Witkowski, M.; Weeks, T.L.; Hazen, S.L. Gut Microbiota and Cardiovascular Disease. Circ. Res. 2020, 127, 553–570. [Google Scholar] [CrossRef]
- Tang, W.H.; Wang, Z.; Li, X.S.; Fan, Y.; Li, D.S.; Wu, Y.; Hazen, S.L. Increased Trimethylamine N-Oxide Portends High Mortality Risk Independent of Glycemic Control in Patients with Type 2 Diabetes Mellitus. Clin. Chem. 2017, 63, 297–306. [Google Scholar] [CrossRef] [PubMed]
- Zhao, L. The gut microbiota and obesity: From correlation to causality. Nat. Rev. Microbiol. 2013, 11, 639–647. [Google Scholar] [CrossRef]
- Vrieze, A.; Van Nood, E.; Holleman, F.; Salojarvi, J.; Kootte, R.S.; Bartelsman, J.F.; Dallinga-Thie, G.M.; Ackermans, M.T.; Serlie, M.J.; Oozeer, R.; et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143, 913–916.e7. [Google Scholar] [CrossRef]
- Shah, J.; Cheong, Z.Y.; Tan, B.; Wong, D.; Liu, X.; Chua, J. Dietary Intake and Diabetic Retinopathy: A Systematic Review of the Literature. Nutrients 2022, 14, 5021. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Lo, A.C.Y. Diabetic Retinopathy: Pathophysiology and Treatments. Int. J. Mol. Sci. 2018, 19, 1816. [Google Scholar] [CrossRef] [PubMed]
- Rodriguez, M.L.; Perez, S.; Mena-Molla, S.; Desco, M.C.; Ortega, A.L. Oxidative Stress and Microvascular Alterations in Diabetic Retinopathy: Future Therapies. Oxidative Med. Cell. Longev. 2019, 2019, 4940825. [Google Scholar] [CrossRef] [PubMed]
- Kupis, M.; Samelska, K.; Szaflik, J.; Skopinski, P. Novel therapies for diabetic retinopathy. Cent. Eur. J. Immunol. 2022, 47, 102–108. [Google Scholar] [CrossRef]
- Kastelan, S.; Oreskovic, I.; Biscan, F.; Kastelan, H.; Gverovic Antunica, A. Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochem. Med. 2020, 30, 030502. [Google Scholar] [CrossRef]
- Thomas, R.L.; Halim, S.; Gurudas, S.; Sivaprasad, S.; Owens, D.R. IDF Diabetes Atlas: A review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018. Diabetes Res. Clin. Pract. 2019, 157, 107840. [Google Scholar] [CrossRef]
- Forrester, J.V.; Kuffova, L.; Delibegovic, M. The Role of Inflammation in Diabetic Retinopathy. Front. Immunol. 2020, 11, 583687. [Google Scholar] [CrossRef]
- Tang, J.; Kern, T.S. Inflammation in diabetic retinopathy. Prog. Retin. Eye Res. 2011, 30, 343–358. [Google Scholar] [CrossRef]
- Santiago, A.R.; Boia, R.; Aires, I.D.; Ambrosio, A.F.; Fernandes, R. Sweet Stress: Coping With Vascular Dysfunction in Diabetic Retinopathy. Front. Physiol. 2018, 9, 820. [Google Scholar] [CrossRef]
- Altmann, C.; Schmidt, M.H.H. The Role of Microglia in Diabetic Retinopathy: Inflammation, Microvasculature Defects and Neurodegeneration. Int. J. Mol. Sci. 2018, 19, 110. [Google Scholar] [CrossRef]
- Whitehead, M.; Wickremasinghe, S.; Osborne, A.; Van Wijngaarden, P.; Martin, K.R. Diabetic retinopathy: A complex pathophysiology requiring novel therapeutic strategies. Expert. Opin. Biol. Ther. 2018, 18, 1257–1270. [Google Scholar] [CrossRef] [PubMed]
- Rubsam, A.; Parikh, S.; Fort, P.E. Role of Inflammation in Diabetic Retinopathy. Int. J. Mol. Sci. 2018, 19, 942. [Google Scholar] [CrossRef] [PubMed]
- Kastelan, S.; Tomic, M.; Gverovic Antunica, A.; Salopek Rabatic, J.; Ljubic, S. Inflammation and pharmacological treatment in diabetic retinopathy. Mediat. Inflamm. 2013, 2013, 213130. [Google Scholar] [CrossRef]
- Gouliopoulos, N.S.; Kalogeropoulos, C.; Lavaris, A.; Rouvas, A.; Asproudis, I.; Garmpi, A.; Damaskos, C.; Garmpis, N.; Kostakis, A.; Moschos, M.M. Association of serum inflammatory markers and diabetic retinopathy: A review of literature. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 7113–7128. [Google Scholar] [CrossRef]
- Yang, J.; Liu, Z. Mechanistic Pathogenesis of Endothelial Dysfunction in Diabetic Nephropathy and Retinopathy. Front. Endocrinol. 2022, 13, 816400. [Google Scholar] [CrossRef]
- Duh, E.J.; Sun, J.K.; Stitt, A.W. Diabetic retinopathy: Current understanding, mechanisms, and treatment strategies. JCI Insight 2017, 2, e93751. [Google Scholar] [CrossRef] [PubMed]
- Fu, Z.; Chen, C.T.; Cagnone, G.; Heckel, E.; Sun, Y.; Cakir, B.; Tomita, Y.; Huang, S.; Li, Q.; Britton, W.; et al. Dyslipidemia in retinal metabolic disorders. EMBO Mol. Med. 2019, 11, e10473. [Google Scholar] [CrossRef]
- Lu, L.; Jiang, Y.; Jaganathan, R.; Hao, Y. Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review. J. Ophthalmol. 2018, 2018, 1694187. [Google Scholar] [CrossRef]
- Sweeney, M.; Foldes, G. It Takes Two: Endothelial-Perivascular Cell Cross-Talk in Vascular Development and Disease. Front. Cardiovasc. Med. 2018, 5, 154. [Google Scholar] [CrossRef]
- Simo-Servat, O.; Hernandez, C.; Simo, R. Diabetic Retinopathy in the Context of Patients with Diabetes. Ophthalmic Res. 2019, 62, 211–217. [Google Scholar] [CrossRef]
- Stitt, A.W.; Curtis, T.M.; Chen, M.; Medina, R.J.; McKay, G.J.; Jenkins, A.; Gardiner, T.A.; Lyons, T.J.; Hammes, H.P.; Simo, R.; et al. The progress in understanding and treatment of diabetic retinopathy. Prog. Retin. Eye Res. 2016, 51, 156–186. [Google Scholar] [CrossRef]
- Maniadakis, N.; Konstantakopoulou, E. Cost Effectiveness of Treatments for Diabetic Retinopathy: A Systematic Literature Review. Pharmacoeconomics 2019, 37, 995–1010. [Google Scholar] [CrossRef] [PubMed]
- Manning, B.D.; Toker, A. AKT/PKB Signaling: Navigating the Network. Cell 2017, 169, 381–405. [Google Scholar] [CrossRef]
- Alam, S.; Sarker, M.M.R.; Sultana, T.N.; Chowdhury, M.N.R.; Rashid, M.A.; Chaity, N.I.; Zhao, C.; Xiao, J.; Hafez, E.E.; Khan, S.A.; et al. Antidiabetic Phytochemicals From Medicinal Plants: Prospective Candidates for New Drug Discovery and Development. Front. Endocrinol. 2022, 13, 800714. [Google Scholar] [CrossRef] [PubMed]
- Aryaeian, N.; Sedehi, S.K.; Arablou, T. Polyphenols and their effects on diabetes management: A review. Med. J. Islam. Repub. Iran. 2017, 31, 134. [Google Scholar] [CrossRef] [PubMed]
- Delmas, D.; Cornebise, C.; Courtaut, F.; Xiao, J.; Aires, V. New Highlights of Resveratrol: A Review of Properties against Ocular Diseases. Int. J. Mol. Sci. 2021, 22, 1295. [Google Scholar] [CrossRef]
- Wang, J.; Li, M.; Geng, Z.; Khattak, S.; Ji, X.; Wu, D.; Dang, Y. Role of Oxidative Stress in Retinal Disease and the Early Intervention Strategies: A Review. Oxid. Med. Cell. Longev. 2022, 2022, 7836828. [Google Scholar] [CrossRef]
- Kang, Q.; Yang, C. Oxidative stress and diabetic retinopathy: Molecular mechanisms, pathogenetic role and therapeutic implications. Redox Biol. 2020, 37, 101799. [Google Scholar] [CrossRef]
- Keegan, G.; Pardhan, S.; Chichger, H. Lutein and zeaxanthin attenuates VEGF-induced neovascularisation in human retinal microvascular endothelial cells through a Nox4-dependent pathway. Exp. Eye Res. 2020, 197, 108104. [Google Scholar] [CrossRef]
- Mthembu, S.X.H.; Mazibuko-Mbeje, S.E.; Moetlediwa, M.T.; Muvhulawa, N.; Silvestri, S.; Orlando, P.; Nkambule, B.B.; Muller, C.J.F.; Ndwandwe, D.; Basson, A.K.; et al. Sulforaphane: A nutraceutical against diabetes-related complications. Pharmacol. Res. 2023, 196, 106918. [Google Scholar] [CrossRef]
- Tanito, M.; Masutani, H.; Kim, Y.C.; Nishikawa, M.; Ohira, A.; Yodoi, J. Sulforaphane induces thioredoxin through the antioxidant-responsive element and attenuates retinal light damage in mice. Investig. Ophthalmol. Vis. Sci. 2005, 46, 979–987. [Google Scholar] [CrossRef]
- Valle, M.S.; Russo, C.; Malaguarnera, L. Protective role of vitamin D against oxidative stress in diabetic retinopathy. Diabetes Metab. Res. Rev. 2021, 37, e3447. [Google Scholar] [CrossRef] [PubMed]
- Fernandez-Robredo, P.; Gonzalez-Zamora, J.; Recalde, S.; Bilbao-Malave, V.; Bezunartea, J.; Hernandez, M.; Garcia-Layana, A. Vitamin D Protects against Oxidative Stress and Inflammation in Human Retinal Cells. Antioxidants 2020, 9, 838. [Google Scholar] [CrossRef]
- Putz, Z.; Tordai, D.; Hajdu, N.; Vagi, O.E.; Kempler, M.; Bekeffy, M.; Korei, A.E.; Istenes, I.; Horvath, V.; Stoian, A.P.; et al. Vitamin D in the Prevention and Treatment of Diabetic Neuropathy. Clin. Ther. 2022, 44, 813–823. [Google Scholar] [CrossRef]
- Totolici, G.; Tiutiuca, C.; Jurja, S.; Tutunaru, D.; Patrascu, A.M. The role of vitamin D in the onset and progression of diabetic retinopathy. Rom. J. Ophthalmol. 2022, 66, 214–218. [Google Scholar] [CrossRef]
- Jiang, Y.; Liu, L.; Curtiss, E.; Steinle, J.J. Epac1 Blocks NLRP3 Inflammasome to Reduce IL-1beta in Retinal Endothelial Cells and Mouse Retinal Vasculature. Mediat. Inflamm. 2017, 2017, 2860956. [Google Scholar] [CrossRef]
- Gu, J.; Geng, K.; Guo, M.; Huang, W.; Zhao, T.; Li, X.; Xu, Y.H.; Xu, Y. Targeting Pyroptosis: New Insights into the Treatment of Diabetic Microvascular Complications. Evid.-Based Complement. Alternat Med. 2022, 2022, 5277673. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Song, Z.; Li, X.; Xu, S.; Zhou, S.; Jin, X.; Zhang, H. Long noncoding RNA KCNQ1OT1 induces pyroptosis in diabetic corneal endothelial keratopathy. Am. J. Physiol.-Cell Physiol. 2023, 318, C346–C359, Erratum in Am. J. Physiol.-Cell Physiol. 2023, 325, C364. [Google Scholar] [CrossRef]
- Chen, Y.; He, Y.; Zhou, H. The potential role of lncRNAs in diabetes and diabetic microvascular complications. Endocr. J. 2020, 67, 659–668. [Google Scholar] [CrossRef]
- Zhu, X.; Wu, Y.B.; Zhou, J.; Kang, D.M. Upregulation of lncRNA MEG3 promotes hepatic insulin resistance via increasing FoxO1 expression. Biochem. Biophys. Res. Commun. 2016, 469, 319–325. [Google Scholar] [CrossRef] [PubMed]
- You, L.; Wang, N.; Yin, D.; Wang, L.; Jin, F.; Zhu, Y.; Yuan, Q.; De, W. Downregulation of Long Noncoding RNA Meg3 Affects Insulin Synthesis and Secretion in Mouse Pancreatic Beta Cells. J. Cell. Physiol. 2016, 231, 852–862. [Google Scholar] [CrossRef]
- Akerman, I.; Tu, Z.; Beucher, A.; Rolando, D.M.Y.; Sauty-Colace, C.; Benazra, M.; Nakic, N.; Yang, J.; Wang, H.; Pasquali, L.; et al. Human Pancreatic beta Cell lncRNAs Control Cell-Specific Regulatory Networks. Cell Metab. 2017, 25, 400–411. [Google Scholar] [CrossRef]
- Pop-Busui, R.; Boulton, A.J.; Feldman, E.L.; Bril, V.; Freeman, R.; Malik, R.A.; Sosenko, J.M.; Ziegler, D. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care 2017, 40, 136–154. [Google Scholar] [CrossRef]
- Feldman, E.L.; Callaghan, B.C.; Pop-Busui, R.; Zochodne, D.W.; Wright, D.E.; Bennett, D.L.; Bril, V.; Russell, J.W.; Viswanathan, V. Diabetic neuropathy. Nat. Rev. Dis. Primers 2019, 5, 42. [Google Scholar] [CrossRef]
- Callaghan, B.C.; Price, R.S.; Feldman, E.L. Distal Symmetric Polyneuropathy: A Review. JAMA 2015, 314, 2172–2181. [Google Scholar] [CrossRef]
- Callaghan, B.C.; Kerber, K.A.; Lisabeth, L.L.; Morgenstern, L.B.; Longoria, R.; Rodgers, A.; Longwell, P.; Feldman, E.L. Role of neurologists and diagnostic tests on the management of distal symmetric polyneuropathy. JAMA Neurol. 2014, 71, 1143–1149. [Google Scholar] [CrossRef] [PubMed]
- Bril, V.; England, J.; Franklin, G.M.; Backonja, M.; Cohen, J.; Del Toro, D.; Feldman, E.; Iverson, D.J.; Perkins, B.; Russell, J.W.; et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011, 76, 1758–1765. [Google Scholar] [CrossRef]
- Yang, H.; Sloan, G.; Ye, Y.; Wang, S.; Duan, B.; Tesfaye, S.; Gao, L. New Perspective in Diabetic Neuropathy: From the Periphery to the Brain, a Call for Early Detection, and Precision Medicine. Front. Endocrinol. 2019, 10, 929. [Google Scholar] [CrossRef]
- Ling, E.; Lepow, B.; Zhou, H.; Enriquez, A.; Mullen, A.; Najafi, B. The impact of diabetic foot ulcers and unilateral offloading footwear on gait in people with diabetes. Clin. Biomech. 2020, 73, 157–161. [Google Scholar] [CrossRef] [PubMed]
- Jeyam, A.; McGurnaghan, S.J.; Blackbourn, L.A.K.; McKnight, J.M.; Green, F.; Collier, A.; McKeigue, P.M.; Colhoun, H.M.; Investigators, S.B. Diabetic Neuropathy Is a Substantial Burden in People With Type 1 Diabetes and Is Strongly Associated With Socioeconomic Disadvantage: A Population-Representative Study From Scotland. Diabetes Care 2020, 43, 734–742. [Google Scholar] [CrossRef] [PubMed]
- Miyashita, A.; Kobayashi, M.; Yokota, T.; Zochodne, D.W. Diabetic Polyneuropathy: New Strategies to Target Sensory Neurons in Dorsal Root Ganglia. Int. J. Mol. Sci. 2023, 24, 5977. [Google Scholar] [CrossRef] [PubMed]
- Ishibashi, F.; Taniguchi, M.; Kosaka, A.; Uetake, H.; Tavakoli, M. Improvement in Neuropathy Outcomes with Normalizing HbA(1c) in Patients with Type 2 Diabetes. Diabetes Care 2019, 42, 110–118. [Google Scholar] [CrossRef] [PubMed]
- Pop-Busui, R.; Lu, J.; Brooks, M.M.; Albert, S.; Althouse, A.D.; Escobedo, J.; Green, J.; Palumbo, P.; Perkins, B.A.; Fred Whitehouse, F.; et al. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care 2013, 36, 3208–3215. [Google Scholar] [CrossRef]
- Hébert, H.L.; Veluchamy, A.; Torrance, N.; Smith, B.H. Risk factors for neuropathic pain in diabetes mellitus. Pain 2017, 158, 560–568. [Google Scholar] [CrossRef]
- Raputova, J.; Srotova, I.; Vlckova, E.; Sommer, C.; Üçeyler, N.; Birklein, F.; Rittner, H.L.; Rebhorn, C.; Adamova, B.; Kovalova, I.; et al. Sensory phenotype and risk factors for painful diabetic neuropathy: A cross-sectional observational study. Pain 2017, 158, 2340–2353. [Google Scholar] [CrossRef]
- Feldman, E.L.; Nave, K.A.; Jensen, T.S.; Bennett, D.L. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neuron 2017, 93, 1296–1313. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.; Kim, J.J.; Yoon, Y.S. Emerging therapy for diabetic neuropathy: Cell therapy targeting vessels and nerves. Endocr. Metab. Immune Disord. Drug Targets 2012, 12, 168–178. [Google Scholar] [CrossRef] [PubMed]
- Komai, H. Vascular Disease and Diabetes. Ann. Vasc. Dis. 2024, 17, 109–113. [Google Scholar] [CrossRef]
- Zochodne, D.W. Diabetes and the plasticity of sensory neurons. Neurosci. Lett. 2015, 596, 60–65. [Google Scholar] [CrossRef]
- Sugimoto, K.; Murakawa, Y.; Sima, A.A. Expression and localization of insulin receptor in rat dorsal root ganglion and spinal cord. J. Peripher. Nerv. Syst. 2002, 7, 44–53. [Google Scholar] [CrossRef]
- Zochodne, D.W. Diabetic neuropathies: Features and mechanisms. Brain Pathol. 1999, 9, 369–391. [Google Scholar] [CrossRef] [PubMed]
- Pop-Busui, R.; Ang, L.; Boulton, A.J.M.; Feldman, E.L.; Marcus, R.L.; Mizokami-Stout, K.; Singleton, J.R.; Ziegler, D. Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy; American Diabetes Association: Arlington, VA, USA, 2022. [Google Scholar]
- Callaghan, B.C.; Little, A.A.; Feldman, E.L.; Hughes, R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst. Rev. 2012, 6, CD007543. [Google Scholar] [CrossRef] [PubMed]
- Page, N.; Deluca, J.; Crowell, K. Clinical inquiry: What medications are best for diabetic neuropathic pain? J. Fam. Pract. 2012, 61, 691–693. [Google Scholar]
- Akter, S.; Choubey, M.; Mohib, M.M.; Arbee, S.; Sagor, M.A.T.; Mohiuddin, M.S. Stem Cell Therapy in Diabetic Polyneuropathy: Recent Advancements and Future Directions. Brain Sci. 2023, 13, 255. [Google Scholar] [CrossRef]
- Voute, M.; Morel, V.; Pickering, G. Topical Lidocaine for Chronic Pain Treatment. Drug Des. Devel Ther. 2021, 15, 4091–4103. [Google Scholar] [CrossRef] [PubMed]
- Volmer-Thole, M.; Lobmann, R. Neuropathy and Diabetic Foot Syndrome. Int. J. Mol. Sci. 2016, 17, 917. [Google Scholar] [CrossRef] [PubMed]
- Cernea, S.; Raz, I. Management of diabetic neuropathy. Metabolism 2021, 123, 154867. [Google Scholar] [CrossRef]
- Singh, B.; Singh, V.; Krishnan, A.; Koshy, K.; Martinez, J.A.; Cheng, C.; Almquist, C.; Zochodne, D.W. Regeneration of diabetic axons is enhanced by selective knockdown of the PTEN gene. Brain 2014, 137, 1051–1067. [Google Scholar] [CrossRef]
- de la Hoz, C.L.; Cheng, C.; Fernyhough, P.; Zochodne, D.W. A model of chronic diabetic polyneuropathy: Benefits from intranasal insulin are modified by sex and RAGE deletion. Am. J. Physiol. Endocrinol. Metab. 2017, 312, E407–E419. [Google Scholar] [CrossRef]
- Kobayashi, M.; Chandrasekhar, A.; Cheng, C.; Martinez, J.A.; Ng, H.; de la Hoz, C.; Zochodne, D.W. Diabetic polyneuropathy, sensory neurons, nuclear structure and spliceosome alterations: A role for CWC22. Dis. Model. Mech. 2017, 10, 215–224. [Google Scholar] [CrossRef]
- Chandrasekhar, A.; Komirishetty, P.; Areti, A.; Krishnan, A.; Zochodne, D.W. Dual Specificity Phosphatases Support Axon Plasticity and Viability. Mol. Neurobiol. 2021, 58, 391–407. [Google Scholar] [CrossRef] [PubMed]
- Kaburagi, H.; Nagata, T.; Enomoto, M.; Hirai, T.; Ohyagi, M.; Ihara, K.; Yoshida-Tanaka, K.; Ebihara, S.; Asada, K.; Yokoyama, H.; et al. Systemic DNA/RNA heteroduplex oligonucleotide administration for regulating the gene expression of dorsal root ganglion and sciatic nerve. Mol. Ther. Nucleic Acids 2022, 28, 910–919. [Google Scholar] [CrossRef]
- Kapranov, P.; Cheng, J.; Dike, S.; Nix, D.A.; Duttagupta, R.; Willingham, A.T.; Stadler, P.F.; Hertel, J.; Hackermuller, J.; Hofacker, I.L.; et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science 2007, 316, 1484–1488. [Google Scholar] [CrossRef] [PubMed]
- Yao, J.; Wang, X.Q.; Li, Y.J.; Shan, K.; Yang, H.; Wang, Y.N.; Yao, M.D.; Liu, C.; Li, X.M.; Shen, Y.; et al. Long non-coding RNA MALAT1 regulates retinal neurodegeneration through CREB signaling. EMBO Mol. Med. 2022, 14, e16660. [Google Scholar] [CrossRef] [PubMed]
- Wu, G.; Li, X.; Li, M.; Zhang, Z. Long non-coding RNA MALAT1 promotes the proliferation and migration of Schwann cells by elevating BDNF through sponging miR-129-5p. Exp. Cell Res. 2020, 390, 111937. [Google Scholar] [CrossRef] [PubMed]
- Radhakrishnan, R.; Kowluru, R.A. Long Noncoding RNA MALAT1 and Regulation of the Antioxidant Defense System in Diabetic Retinopathy. Diabetes 2021, 70, 227–239. [Google Scholar] [CrossRef]
- Arunkumar, G. LncRNAs: The good, the bad, and the unknown. Biochem. Cell Biol. 2024, 102, 9–27. [Google Scholar] [CrossRef] [PubMed]
- Hussein, R.M. Long non-coding RNAs: The hidden players in diabetes mellitus-related complications. Diabetes Metab. Syndr. 2023, 17, 102872. [Google Scholar] [CrossRef]
- Ebrahimi, A.; Ahmadi, H.; Pourfraidon Ghasrodashti, Z.; Tanide, N.; Shahriarirad, R.; Erfani, A.; Ranjbar, K.; Ashkani-Esfahani, S. Therapeutic effects of stem cells in different body systems, a novel method that is yet to gain trust: A comprehensive review. Bosn. J. Basic. Med. Sci. 2021, 21, 672–701. [Google Scholar] [CrossRef]
- Kubiak, C.A.; Grochmal, J.; Kung, T.A.; Cederna, P.S.; Midha, R.; Kemp, S.W.P. Stem-cell-based therapies to enhance peripheral nerve regeneration. Muscle Nerve 2020, 61, 449–459. [Google Scholar] [CrossRef]
- Streckmann, F.; Balke, M.; Cavaletti, G.; Toscanelli, A.; Bloch, W.; Décard, B.F.; Lehmann, H.C.; Faude, O. Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Med. 2022, 52, 1043–1065. [Google Scholar] [CrossRef]
- Dagar, N.; Das, P.; Bisht, P.; Taraphdar, A.K.; Velayutham, R.; Arumugam, S. Diabetic nephropathy: A twisted thread to unravel. Life Sci. 2021, 278, 119635. [Google Scholar] [CrossRef] [PubMed]
- Umanath, K.; Lewis, J.B. Update on Diabetic Nephropathy: Core Curriculum 2018. Am. J. Kidney Dis. 2018, 71, 884–895. [Google Scholar] [CrossRef] [PubMed]
- Papadopoulou-Marketou, N.; Paschou, S.A.; Marketos, N.; Adamidi, S.; Adamidis, S.; Kanaka-Gantenbein, C. Diabetic nephropathy in type 1 diabetes. Minerva Med. 2018, 109, 218–228. [Google Scholar] [CrossRef] [PubMed]
- Koch, E.A.T.; Nakhoul, R.; Nakhoul, F.; Nakhoul, N. Autophagy in diabetic nephropathy: A review. Int. Urol. Nephrol. 2020, 52, 1705–1712. [Google Scholar] [CrossRef] [PubMed]
- Ying, A.F.; Tang, T.Y.; Jin, A.; Chong, T.T.; Hausenloy, D.J.; Koh, W.P. Diabetes and other vascular risk factors in association with the risk of lower extremity amputation in chronic limb-threatening ischemia: A prospective cohort study. Cardiovasc. Diabetol. 2022, 21, 7. [Google Scholar] [CrossRef]
- Giri, B.; Dey, S.; Das, T.; Sarkar, M.; Banerjee, J.; Dash, S.K. Chronic hyperglycemia mediated physiological alteration and metabolic distortion leads to organ dysfunction, infection, cancer progression and other pathophysiological consequences: An update on glucose toxicity. Biomed. Pharmacother. 2018, 107, 306–328. [Google Scholar] [CrossRef]
- Tonneijck, L.; Muskiet, M.H.; Smits, M.M.; van Bommel, E.J.; Heerspink, H.J.; van Raalte, D.H.; Joles, J.A. Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment. J. Am. Soc. Nephrol. 2017, 28, 1023–1039. [Google Scholar] [CrossRef]
- Calle, P.; Hotter, G. Macrophage Phenotype and Fibrosis in Diabetic Nephropathy. Int. J. Mol. Sci. 2020, 21, 2806. [Google Scholar] [CrossRef]
- Dalla Vestra, M.; Mussap, M.; Gallina, P.; Bruseghin, M.; Cernigoi, A.M.; Saller, A.; Plebani, M.; Fioretto, P. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J. Am. Soc. Nephrol. 2005, 16 (Suppl. S1), S78–S82. [Google Scholar] [CrossRef] [PubMed]
- Wada, J.; Makino, H. Inflammation and the pathogenesis of diabetic nephropathy. Clin. Sci. 2013, 124, 139–152. [Google Scholar] [CrossRef] [PubMed]
- Lim, A. Diabetic nephropathy—Complications and treatment. Int. J. Nephrol. Renovasc Dis. 2014, 7, 361–381. [Google Scholar] [CrossRef] [PubMed]
- Gupta, S.; Dominguez, M.; Golestaneh, L. Diabetic Kidney Disease: An Update. Med. Clin. N. Am. 2023, 107, 689–705. [Google Scholar] [CrossRef]
- Landstra, C.P.; de Koning, E.J.P. COVID-19 and Diabetes: Understanding the Interrelationship and Risks for a Severe Course. Front. Endocrinol. 2021, 12, 649525. [Google Scholar] [CrossRef] [PubMed]
- Al-Waili, N.; Al-Waili, H.; Al-Waili, T.; Salom, K. Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials. Redox Rep. 2017, 22, 99–118. [Google Scholar] [CrossRef] [PubMed]
- Jia, Q.; Yang, R.; Liu, X.F.; Ma, S.F.; Wang, L. Genistein attenuates renal fibrosis in streptozotocin-induced diabetic rats. Mol. Med. Rep. 2019, 19, 423–431. [Google Scholar] [CrossRef]
- Lachin, J.M.; Nathan, D.M.; Group, D.E.R. Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC). Diabetes Care 2021, 44, 2216–2224. [Google Scholar] [CrossRef]
- Bebu, I.; Braffett, B.H.; Schade, D.; Sivitz, W.; Malone, J.I.; Pop-Busui, R.; Lorenzi, G.M.; Lee, P.; Trapani, V.R.; Wallia, A.; et al. An Observational Study of the Equivalence of Age and Duration of Diabetes to Glycemic Control Relative to the Risk of Complications in the Combined Cohorts of the DCCT/EDIC Study. Diabetes Care 2020, 43, 2478–2484. [Google Scholar] [CrossRef]
- Ahmad, J. Management of diabetic nephropathy: Recent progress and future perspective. Diabetes Metab. Syndr. 2015, 9, 343–358. [Google Scholar] [CrossRef]
- Cha, A.S.; Chen, Y.; Fazioli, K.; Rivara, M.B.; Devine, E.B. Microvascular Benefits of New Antidiabetic Agents: A Systematic Review and Network Meta-Analysis of Kidney Outcomes. J. Clin. Endocrinol. Metab. 2021, 106, 1225–1234. [Google Scholar] [CrossRef]
- Tanase, D.M.; Gosav, E.M.; Anton, M.I.; Floria, M.; Seritean Isac, P.N.; Hurjui, L.L.; Tarniceriu, C.C.; Costea, C.F.; Ciocoiu, M.; Rezus, C. Oxidative Stress and NRF2/KEAP1/ARE Pathway in Diabetic Kidney Disease (DKD): New Perspectives. Biomolecules 2022, 12, 1227. [Google Scholar] [CrossRef] [PubMed]
- Charlton, A.; Garzarella, J.; Jandeleit-Dahm, K.A.M.; Jha, J.C. Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes. Biology 2020, 10, 18. [Google Scholar] [CrossRef]
- Eltablawy, N.; Ashour, H.; Rashed, L.A.; Hamza, W.M. Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition. Arch. Physiol. Biochem. 2018, 124, 461–467. [Google Scholar] [CrossRef] [PubMed]
- Ma, T.K.; Kam, K.K.; Yan, B.P.; Lam, Y.Y. Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: Current status. Br. J. Pharmacol. 2010, 160, 1273–1292. [Google Scholar] [CrossRef]
- Mazzieri, A.; Porcellati, F.; Timio, F.; Reboldi, G. Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection. Int. J. Mol. Sci. 2024, 25, 3969. [Google Scholar] [CrossRef]
- Zhang, Y.; Sun, Y.; Peng, R.; Liu, H.; He, W.; Zhang, L.; Peng, H.; Zhang, Z. The Long Noncoding RNA 150Rik Promotes Mesangial Cell Proliferation via miR-451/IGF1R/p38 MAPK Signaling in Diabetic Nephropathy. Cell Physiol. Biochem. 2018, 51, 1410–1428. [Google Scholar] [CrossRef]
- Huang, S.; Xu, Y.; Ge, X.; Xu, B.; Peng, W.; Jiang, X.; Shen, L.; Xia, L. Long noncoding RNA NEAT1 accelerates the proliferation and fibrosis in diabetic nephropathy through activating Akt/mTOR signaling pathway. J. Cell Physiol. 2019, 234, 11200–11207. [Google Scholar] [CrossRef]
- Mao, Q.; Chen, C.; Liang, H.; Zhong, S.; Cheng, X.; Li, L. Astragaloside IV inhibits excessive mesangial cell proliferation and renal fibrosis caused by diabetic nephropathy via modulation of the TGF-beta1/Smad/miR-192 signaling pathway. Exp. Ther. Med. 2019, 18, 3053–3061. [Google Scholar] [CrossRef]
- Hanson, R.L.; Craig, D.W.; Millis, M.P.; Yeatts, K.A.; Kobes, S.; Pearson, J.V.; Lee, A.M.; Knowler, W.C.; Nelson, R.G.; Wolford, J.K. Identification of PVT1 as a candidate gene for end-stage renal disease in type 2 diabetes using a pooling-based genome-wide single nucleotide polymorphism association study. Diabetes 2007, 56, 975–983. [Google Scholar] [CrossRef]
- Lin, B.; Ma, Y.Y.; Wang, J.W. Nano-Technological Approaches for Targeting Kidney Diseases With Focus on Diabetic Nephropathy: Recent Progress, and Future Perspectives. Front. Bioeng. Biotechnol. 2022, 10, 870049. [Google Scholar] [CrossRef]
- American Diabetes, A. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2019. Diabetes Care 2019, 42, S90–S102. [Google Scholar] [CrossRef] [PubMed]
- Ramos, A.M.; Fernandez-Fernandez, B.; Perez-Gomez, M.V.; Carriazo Julio, S.M.; Sanchez-Nino, M.D.; Sanz, A.; Ruiz-Ortega, M.; Ortiz, A. Design and optimization strategies for the development of new drugs that treat chronic kidney disease. Expert. Opin. Drug Discov. 2020, 15, 101–115. [Google Scholar] [CrossRef] [PubMed]
- Faustino, C.; Pinheiro, L. Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy. Pharmaceutics 2020, 12, 29. [Google Scholar] [CrossRef]
- Rubin, J.D.; Barry, M.A. Improving Molecular Therapy in the Kidney. Mol. Diagn. Ther. 2020, 24, 375–396. [Google Scholar] [CrossRef]
- van Alem, C.M.A.; Boonstra, M.; Prins, J.; Bezhaeva, T.; van Essen, M.F.; Ruben, J.M.; Vahrmeijer, A.L.; van der Veer, E.P.; de Fijter, J.W.; Reinders, M.E.; et al. Local delivery of liposomal prednisolone leads to an anti-inflammatory profile in renal ischaemia-reperfusion injury in the rat. Nephrol. Dial. Transplant. 2018, 33, 44–53. [Google Scholar] [CrossRef] [PubMed]
- Tandon, N.; Ali, M.K.; Narayan, K.M. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: Implications of the results of recent clinical trials in type 2 diabetes. Am. J. Cardiovasc. Drugs 2012, 12, 7–22. [Google Scholar] [CrossRef]
- Milligan, S. Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation. J. Diabetes Complicat. 2016, 30, 1177–1185. [Google Scholar] [CrossRef]
- Tilinca, M.C.; Tiuca, R.A.; Tilea, I.; Varga, A. The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients. J. Pers. Med. 2021, 11, 1249. [Google Scholar] [CrossRef]
- Hussain, S.; Chowdhury, T.A. The Impact of Comorbidities on the Pharmacological Management of Type 2 Diabetes Mellitus. Drugs 2019, 79, 231–242. [Google Scholar] [CrossRef]
- Tsapas, A.; Avgerinos, I.; Karagiannis, T.; Malandris, K.; Manolopoulos, A.; Andreadis, P.; Liakos, A.; Matthews, D.R.; Bekiari, E. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis. Ann. Intern. Med. 2020, 173, 278–286. [Google Scholar] [CrossRef]
- Wronka, M.; Krzemińska, J.; Młynarska, E.; Rysz, J.; Franczyk, B. New Insights into the Use of Liraglutide-Impact on Cardiovascular Risk and Microvascular Outcomes. Biomedicines 2023, 11, 1159. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yapislar, H.; Gurler, E.B. Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment. Biomedicines 2024, 12, 1958. https://doi.org/10.3390/biomedicines12091958
Yapislar H, Gurler EB. Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment. Biomedicines. 2024; 12(9):1958. https://doi.org/10.3390/biomedicines12091958
Chicago/Turabian StyleYapislar, Hande, and Esra Bihter Gurler. 2024. "Management of Microcomplications of Diabetes Mellitus: Challenges, Current Trends, and Future Perspectives in Treatment" Biomedicines 12, no. 9: 1958. https://doi.org/10.3390/biomedicines12091958